Drugs / Duvarizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05322187 | Apr 2022 → Sep 2023 | childhood malignant neoplasm, hepatoblastoma, transitional cell neoplasm | RenJi Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Duvarizumab | “PD-L1 inhibitor (Duvarizumab)” NCT05322187 ↗ |
| Action | Inhibit | “PD-L1 inhibitor (Duvarizumab)” NCT05322187 ↗ |